Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Endpoints described the transaction as another James Sabry-led BD move to refresh Genentech's targeted oncology pipeline, with the $80M upfront sized to a…
PharmaTimes highlighted Genentech's stated enthusiasm for leveraging Hanmi's MAPK-pathway insights, framing the $910M biobucks structure as standard for Phase…
Korean coverage characterized belvarafenib as Hanmi's flagship validated oncology asset, with Genentech advancing it through a global Phase 1b combo with…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Genentech (Roche Group) licensed exclusive worldwide rights (excluding South Korea) to Hanmi's pan-RAF inhibitor HM95573 (Phase 1) for $80M upfront plus up to $830M in development, regulatory, and commercialization milestones (~$910M total) plus tiered double-digit royalties. Strategic for Roche's targeted oncology program in BRAF/CRAF-driven tumors. Closed Q4 2016.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Genentech, Inc. (Roche Group) / Hanmi Pharmaceutical Co. Ltd. (this deal) | 2016 | $910M | — |
| Genentech, Inc. (Roche Group) / Tanox Inc. | 2006 | $919M | 80 |
| Genentech, Inc. (Roche Group) / Astex Pharmaceuticals | 2026 | $490M | 58 |
| Genentech, Inc. (Roche Group) / Affimed N.V. | 2018 | $5.1B | — |
| Genentech, Inc. (Roche Group) / Regor Pharmaceuticals Inc. | 2024 | $850M | — |
| Genentech, Inc. (Roche Group) / OMass Therapeutics Ltd. | 2025 | $420M | — |
| Genentech, Inc. (Roche Group) / MaxCyte, Inc. | 2026 | — | — |
← Browse all deals · How we score deals
More: 2016 deals · Genentech, Inc. (Roche Group) deals · Oncology deals